Advertisement

BrainStorm Cell Therapeutics Inc., an adult stem cell technology and central nervous system therapeutics company, said it will collaborate with Massachusetts General Hospital and the University of Massachusetts Medical School on a human clinical trial for its NurOwn experimental treatment for amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease).

The memorandum of understanding between the Massachusetts entities and BrainStorm, of Israel and New York, leads up to BrainStorm’s applying for U.S. Food and Drug Administration (FDA) approval to start ALS human clinical trials in the United States. This U.S. trial will be conducted after FDA approvals and in parallel with trials BrainStorm is running in Israel with the Hadassah Medical Center.

SOURCE

Advertisement
Advertisement